CION Ameerpet
Ovarian cancer is not rare in India, and it is not as common as breast or cervical cancer either. The most recent national estimate puts it at 45,566 new cases and 28,782 deaths in a year. This page explains where those figures come from, why different websites quote different ones, and — more usefully — what a national average can and cannot tell you about your own risk.
Around 45,566 women in India are diagnosed with ovarian cancer in a year, and about 28,782 die of it. Those are the most recent estimates for the country from the International Agency for Research on Cancer, whose Global Cancer Observatory publishes a national factsheet built from India's cancer registries.
That makes ovarian cancer the fourth most commonly diagnosed cancer in Indian women — behind breast, cervical and oral cancer — and the second commonest cancer of the female reproductive organs after cervical cancer. It accounts for roughly one in every 17 cancers diagnosed in women here.
The more telling rank is the other one. Ovarian cancer is the third leading cause of cancer death in Indian women, behind only breast and cervical cancer. A disease that sits fourth in how often it is diagnosed and third in how often it kills is a disease that is being found too late — and that, rather than the raw case count, is the number worth understanding.
Most ovarian cancer India statistics quoted online come from one of two places: these modelled IARC estimates, or the ICMR National Cancer Registry Programme, which counts real cases in defined populations. They answer slightly different questions, which is why the figures you find rarely match each other exactly.
The estimated annual number of ovarian cancer diagnoses in India — about 5.8% of all cancers diagnosed in women, and ninth among all cancers in both sexes.
Third only to breast and cervical cancer as a cause of cancer death in Indian women, despite being the fourth commonest diagnosis.
The cumulative risk of developing ovarian cancer before the age of 75 for an average Indian woman is roughly 0.67% — a real risk, but a small one.
Ovarian cancer kills out of proportion to how often it occurs because of when it is found. In the ICMR National Cancer Registry Programme's review of ovarian cancers in India, hospital registry data showed that only 29% of women were diagnosed while the disease was still localised; 41.9% had locally advanced or locoregional disease and a further 29% already had distant metastasis. Roughly seven women in ten, in other words, were diagnosed after the cancer had spread beyond the ovary — which is what a disease with no effective screening test looks like in the data. Source: Chaturvedi M, Krishnan S, Das P, et al. Descriptive Epidemiology of Ovarian Cancers in India: A Report from the National Cancer Registry Programme. Indian Journal of Gynecologic Oncology (2023); ICMR-NCDIR.
A statistic is only useful if you know what question it answers. Here is every figure commonly quoted for ovarian cancer in India, with the caveat that belongs beside it.
| Measure | India | What it actually tells you |
|---|---|---|
| New cases a year | 45,566 women | A modelled national estimate, not a headcount. India has no complete national cancer register, so the figure is built by applying registry rates to the national population. |
| Deaths a year | 28,782 women | Estimated the same way. Deaths are about 63% of the number of new cases in a year; for breast cancer the comparable figure is about 40%. That gap is a crude marker of late diagnosis, not a survival rate. |
| Rank among cancers in women | 4th | After breast, cervical and oral cancer. Second among gynaecological cancers, behind cervical cancer and ahead of cancer of the uterine lining. |
| Rank as a cause of cancer death in women | 3rd | Behind breast and cervical cancer only. The mismatch between this rank and the one above is the whole problem in a single line. |
| Age-standardised incidence rate | About 6 per 100,000 women a year | The rate once differences in age structure are removed, so countries can be compared. India's rate is lower than the rates reported in North America and Northern Europe. |
| Cumulative risk to age 75 | About 0.67%, or 1 woman in 150 | The chance an average Indian woman is diagnosed before 75. It is an average across the whole population and does not describe a woman with a BRCA variant or a strong family history. |
| Age when rates climb | From the mid-30s, peaking at 55–64 | Registry data show incidence rising from about age 35 and peaking between 55 and 64. Ovarian cancer still occurs in younger women, but it is uncommon before 35. |
*Sources: IARC Global Cancer Observatory (GLOBOCAN) India factsheet, 2024 estimates; ICMR National Cancer Registry Programme; Murthy NS et al., Asian Pacific Journal of Cancer Prevention, on age-specific incidence trends across Indian registries. Figures are national estimates and are revised each time IARC and ICMR publish.
If you have searched this question, you have already met four or five different figures. They are not contradictions so much as different measurements, quoted without their labels. Here is how to tell which one you are looking at.
India does not have a complete national cancer register. What exists is a network of population-based registries covering defined districts and cities, plus hospital-based registries that record the patients who reach particular hospitals. The national totals you read are estimates: registry rates applied to the national population, adjusted for age and sex.
That is standard international practice and the estimates are good ones, but they carry an uncertainty range that headlines drop. When a page says 45,566 women were diagnosed, the accurate reading is this many are estimated to have been diagnosed. The difference matters when two sources disagree by a few thousand cases.
Global estimates are published in cycles, and registry reports lag the years they describe by several years, because a cancer registry has to wait for records to be complete before it can report. A page quoting 2020 estimates and a page quoting the latest ones will disagree, and neither is wrong.
This is why the direction of travel is more useful than any single year's number. Across most Indian registries the incidence of ovarian cancer has been rising slowly for decades — partly a real increase, partly better diagnosis and better registration.
A crude rate is simply cases divided by population. An age-standardised rate re-weights that to a standard age distribution, so a young country and an ageing one can be compared fairly. Because ovarian cancer is largely a disease of women over 50, the two numbers differ substantially in India, which has a young population.
If you are comparing India with the United Kingdom or the United States, use age-standardised rates. If you want to know how many beds, scans and chemotherapy chairs a state needs, the crude count is the relevant one. Quoting one and labelling it the other is the commonest error on health websites.
Incidence is new cases in a year. Mortality is deaths in a year. Prevalence is how many women are alive with a diagnosis made in the last five years — a larger number than either, because it accumulates. All three exist for ovarian cancer in India, and all three get quoted as how many women have ovarian cancer.
When you see a figure, look for the unit. Cases per year, deaths per year, cases per 100,000 women per year, and five-year prevalent cases are four different measurements, and only one of them answers the question you are probably asking.
Registry reports show ovarian cancer among the ten commonest cancers in some Indian registries and outside the top ten in others, with age-adjusted rates varying several-fold between regions. Registries in parts of the North East report higher rates in younger age bands than the national picture suggests.
Some of that variation is real — differences in childbearing patterns, breastfeeding, age at menopause and genetic background. Some is an artefact of how completely cancers are registered in different places. A single national figure is an average of both.
Statistics drawn from hospital-based registries — including the stage-at-diagnosis figures quoted on this page — describe women who reached a cancer hospital and were registered there. Women who never reached one are missing from them.
That does not make them useless; hospital data are the only source for stage at presentation and treatment given, and they are the best evidence available on how late ovarian cancer is found in India. It does mean they should not be read as a random sample of Indian women.
Every figure on this page describes a population. Your own risk depends on your age, your family history, whether you carry a BRCA1, BRCA2 or Lynch-syndrome variant, how many pregnancies you have had, and how long you used hormonal contraception. Those factors move individual risk far more than any national average.
The practical use of population statistics is to tell you which questions are worth asking — about your family history, about symptoms that persist, about whether genetic testing applies to you. They cannot tell you what is happening inside your own abdomen. Only an assessment can, and you can book one free.
The cumulative risk figure is an average across every woman in the country, most of whom have no particular risk factor. If any of the following describes you, your own risk sits above that average and is worth assessing properly rather than estimating from a national table.
A mother, sister or daughter diagnosed with ovarian cancer raises your risk meaningfully, and raises it further if she was diagnosed young or more than one relative is affected.
If a relative has tested positive for a BRCA1 or BRCA2 variant, testing you is a straightforward blood or saliva test — and a negative result ends the question for you and your children.
Breast cancer in a relative under 50, breast and ovarian cancer in the same woman, or male breast cancer are the classic pointers to an inherited variant that also raises ovarian risk.
Clusters of bowel and endometrial cancer can indicate Lynch syndrome, which carries a raised ovarian cancer risk alongside the better-known bowel one.
Bloating, feeling full quickly, pelvic pain or urinary urgency on more days than not, for three weeks or more, is an examination question rather than a statistics question. A tumour is rarely something you can feel yourself.
Incidence peaks between 55 and 64, and the benign explanations for pelvic symptoms thin out after the menopause. Age changes what the same symptom means.
None of these means you have or will get ovarian cancer. Each one means a national average is the wrong tool, and a consultation that takes a proper family history is the right one. Genetic counselling and BRCA testing are delivered in-house at CION.
A 45-minute consultation, a proper family-history assessment and — where it is warranted — an examination, an ultrasound and a discussion about genetic testing. Most women leave reassured with a clear answer instead of a statistic.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
No referral needed and no cost for the first consultation. If your risk turns out to be an ordinary one, we will say so plainly rather than book you in for surveillance you do not need.
This is the sequence a specialist works through when a woman arrives having read the numbers and wanting to know what they mean for her. It takes one consultation, and for most women it ends at step three.
About one Indian woman in 150 develops ovarian cancer before the age of 75. That is the starting point for a woman with no family history and no symptoms — a real but small risk, and one that does not justify tests or surveillance on its own.
Three generations, both sides, and every cancer with the age at diagnosis. Ovarian, breast, bowel and endometrial cancers matter most. This is the single step that changes the answer most often, and it is the step most likely to be skipped in a five-minute appointment — which is why a CION consultation runs to 45 minutes.
Never having been pregnant, early first period, late menopause and endometriosis push risk up modestly. Pregnancy, breastfeeding and years of combined hormonal contraception push it down. These shift the baseline; they rarely decide anything by themselves, and no one should choose a contraceptive on this basis alone.
There is no effective screening test for ovarian cancer — not CA-125, not ultrasound, not the two together, and not for BRCA carriers either. The UKCTOCS trial followed more than 200,000 women in the United Kingdom for years and found that annual screening did not reduce deaths from ovarian cancer. Anyone offering you a screening package that promises to catch it early is selling something the evidence does not support.
Since screening does not work, symptom awareness is what is left. Bloating, early satiety, pelvic pain and urinary urgency — new, persistent, and present on more than 12 days a month — is the pattern that earns an examination. It is worth knowing how quickly ovarian cancer actually grows, because the answer explains why waiting six months is the thing to avoid.
Where the family history points to an inherited variant, genetic counselling comes first and testing follows a conversation, never a sales pitch. CION delivers genetic counselling and BRCA and HRD testing in-house across its centres, and a result changes what is recommended for your sisters and daughters as much as for you.
Nothing in this sequence requires a scan for most women. A history, an examination and an honest conversation answer the question for the large majority.
People rarely search national statistics out of academic interest. They search them because a relative has been diagnosed, or because a symptom has not settled, and the numbers are a way of asking should I be worried? A table cannot answer that. A consultation can.
Your first consultation at CION is free and runs to about 45 minutes — long enough to take a three-generation family history properly, examine you, and decide what testing is actually warranted. We do not order tests you do not need. A CA-125 in a woman with no symptoms and no family history answers nothing and worries everyone, and we will say so rather than run it to look thorough.
Where an assessment does find ovarian cancer, CION delivers medical oncology in-house: chemotherapy and maintenance therapy across 35+ centres in Telangana and Andhra Pradesh, alongside genetic counselling, BRCA and HRD testing, nutrition support and structured follow-up. Debulking and other gynaecologic-oncology surgery, HIPEC, intraperitoneal chemotherapy and PET-CT are coordinated with specialist partner centres and may be billed there. We would rather be straightforward about that division now than have you discover it mid-treatment.
Free, unhurried and with a specialist. Long enough for the family history that decides what testing you do and do not need.
Counselling before testing, then BRCA and HRD testing where it is indicated — with a plan for what a result means for your sisters and daughters.
Cases that raise a question are reviewed by medical oncology, imaging and pathology together, rather than decided by one clinician.
Chemotherapy and follow-up delivered near where you live, across Telangana and Andhra Pradesh, instead of repeat trips to a single city hospital.
Once people have the incidence numbers, they want the survival ones. Those are far shakier ground in India, and it is more honest to explain why than to publish a percentage that sounds authoritative. Population-level survival estimates here rest on registries with incomplete follow-up; published figures are usually several years old, average across every substage and tumour subtype, and mix women who had complete surgery with women who had none. A single percentage built on all of that will not describe any individual woman.
Stage matters more than any national average. So does tumour subtype, so does whether all visible disease could be removed at surgery, and so does response to platinum-based chemotherapy. Two women with the same stage on paper can have genuinely different outlooks, which is why reading published life-expectancy figures is best done with an oncologist who knows your case. It is also why even advanced ovarian cancer is not a settled verdict — ovarian cancer is unusually chemo-sensitive, and remission is common.
The one comparison CION does publish is its own one-year survival against the national figure, so the difference is visible rather than implied. For ovarian cancer, 81.0% of CION patients are alive at one year, against a national figure of 73.7%. That is one-year survival across a treated population — not a cure rate, and not a prediction for any individual.
CION ovarian cancer patients alive at one year from diagnosis. *One-year survival, CION treated population.
The comparable national figure for ovarian cancer. *One-year survival; national registry data.
One-year survival is not a cure rate and not a forecast for you. Stage at diagnosis, tumour subtype, completeness of surgery and general health matter far more to your own outlook.
*One-year survival rates. CION figures reflect CION's treated patient population; national figures are drawn from published Indian cancer registry data. Survival statistics describe groups, not individuals — discuss your own prognosis with your treating oncologist.
About 45,566 women in India are estimated to be diagnosed with ovarian cancer in a year, and about 28,782 die of it. Those are the most recent national estimates from the International Agency for Research on Cancer, whose Global Cancer Observatory builds them by applying rates measured in India's population-based cancer registries to the national population. They are careful estimates rather than a headcount, because India has no complete national cancer register, and they are revised each time IARC and the ICMR publish. Expect the exact figure to differ slightly between sources depending on which year of estimates each one is quoting.
It is considerably less common than either. Breast cancer accounts for roughly 237,000 diagnoses in Indian women a year and cervical cancer about 79,000, against roughly 45,500 for ovarian cancer. Ovarian cancer ranks fourth among cancers diagnosed in Indian women, after breast, cervical and oral cancer, and second among gynaecological cancers behind cervical cancer. The picture changes when you look at deaths rather than diagnoses: ovarian cancer is the third leading cause of cancer death in Indian women. It kills out of proportion to how often it occurs because it is usually found after it has spread, and because there is no screening test that works.
For an average Indian woman, the cumulative risk of being diagnosed before the age of 75 is around 0.67 per cent — roughly one woman in 150. That figure is an average across the entire female population, most of whom carry no particular risk factor, so it describes a group rather than a person. Your own risk is higher if a close relative had ovarian cancer, if breast cancer occurred young or in a man in your family, if bowel and uterine cancers cluster on one side, or if you carry a BRCA1, BRCA2 or Lynch-syndrome variant. It is lower if you have had pregnancies, breastfed, or used combined hormonal contraception for several years.
Registry data suggest a slow rise over several decades in most Indian registries, though the size of the increase varies considerably between regions. Part of that is likely to be real, reflecting later childbearing, fewer pregnancies, shorter breastfeeding and longer life expectancy, since ovarian cancer is largely a disease of women over 50. Part of it reflects better diagnosis and more complete cancer registration, which make more of the existing disease visible in the statistics. Both explanations point the same way for you as an individual: the important change is not the trend line but whether symptoms that persist are looked at promptly.
Indian registry data show incidence beginning to climb from around the age of 35 and peaking between 55 and 64. That is the pattern for the commonest epithelial ovarian cancers. It does not mean younger women are exempt: germ-cell and borderline ovarian tumours occur mainly in women in their teens, twenties and thirties, and behave quite differently from the cancers that dominate the older age groups. Some Indian registries, particularly in the North East, report higher rates in younger age bands than the national average suggests. The practical point is that a persistent symptom deserves the same assessment at 38 as at 58 — only the likely explanations differ.
Usually because they are quoting different measurements or different years, without labelling either. Global estimates and registry reports are published in cycles, so a page citing figures from a few years ago will disagree with one citing the latest set, and neither is wrong. Crude rates and age-standardised rates differ substantially in a country with a young population like India. Incidence, mortality and five-year prevalence are three different numbers that all get described as how many women have ovarian cancer. And hospital-based figures describe the patients who reached a hospital, not the whole population. Check the unit and the year before comparing two figures.
No, and this is the uncomfortable part of the statistics. There is no ovarian cancer screening test proven to save lives — not CA-125, not pelvic ultrasound, not the two combined, and not for women carrying a BRCA variant either. The UKCTOCS trial followed more than 200,000 women in the United Kingdom and found that annual screening did not reduce deaths from ovarian cancer, despite finding some cancers earlier. That is why roughly seven Indian women in ten are diagnosed once the disease has spread beyond the ovary. Symptom awareness and prompt assessment of persistent symptoms are what remain, along with genetic testing for families where an inherited variant is likely.
The first consultation is free and runs to about 45 minutes. CION delivers medical oncology for ovarian cancer in-house — chemotherapy and maintenance therapy across more than 35 centres in Telangana and Andhra Pradesh — along with genetic counselling, BRCA and HRD testing, nutrition support and follow-up care. Debulking and other gynaecologic-oncology surgery, HIPEC, intraperitoneal chemotherapy and PET-CT are coordinated with specialist partner centres and may be billed there, and we say so upfront rather than leaving it to be discovered later. Every case that raises a question is reviewed at a tumour board rather than decided by one doctor alone.